Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Similar articles for PubMed (Select 21715490)

1.

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.

J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.

3.

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR.

J Virol. 2012 Apr;86(8):4394-403. doi: 10.1128/JVI.06973-11. Epub 2012 Feb 15.

4.

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.

J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.

5.

Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT.

J Biol Chem. 2012 Feb 17;287(8):5673-86. doi: 10.1074/jbc.M111.317776. Epub 2011 Dec 13.

6.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

7.

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.

Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT.

J Virol. 2011 Aug;85(16):8217-26. doi: 10.1128/JVI.00756-11. Epub 2011 Jun 8.

8.

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS.

PLoS One. 2012;7(9):e44241. doi: 10.1371/journal.pone.0044241. Epub 2012 Sep 10.

9.

A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.

Guo D, Shi X, Arledge KC, Song D, Jiang L, Fu L, Gong X, Zhang S, Wang X, Zhang L.

J Biol Chem. 2012 Dec 14;287(51):43170-9. doi: 10.1074/jbc.M112.399402. Epub 2012 Oct 25.

10.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

11.

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.

Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR.

J Virol. 2015 Apr;89(8):4201-13. doi: 10.1128/JVI.03608-14. Epub 2015 Jan 28.

PMID:
25631091
12.

Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

J Virol. 2010 May;84(9):4311-20. doi: 10.1128/JVI.02619-09. Epub 2010 Feb 17.

13.

HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.

14.

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.

15.

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E738-47. doi: 10.1073/pnas.1319512111. Epub 2014 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Feb 18;111(7). doi:10.1073/pnas.1403776111. de Val Alda, Natalia [corrected to de Val, Natalia]. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1159.

16.

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ.

Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41.

17.

HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, Chakrabarti BK, Doria-Rose N, Roederer M, Connors M, Mascola JR, Wyatt RT.

J Virol. 2012 Oct;86(20):11231-41. Epub 2012 Aug 8.

18.

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR.

J Virol. 2009 Nov;83(21):10892-907. doi: 10.1128/JVI.01142-09. Epub 2009 Aug 19.

19.

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.

20.

Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations.

Zhang Y, Pan D, Shen Y, Jin N, Liu H, Yao X.

J Mol Model. 2012 Sep;18(9):4517-27. doi: 10.1007/s00894-012-1450-z. Epub 2012 May 29.

PMID:
22643972
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk